---
title: "據報禮來擬以逾 10 億美元收購 Ventyx Biosciences"
description: "禮來正在與 Ventyx Biosciences 進行超過 10 億美元的收購談判，消息來源於《華爾街日報》。此交易可能會使禮來的產品線增加治療炎症性腸病和帕金森病的藥物。Ventyx 的一種實驗性藥物也在中期開發中，旨在治療與肥胖相關的心血管疾病。Ventyx 的股價在盤後交易中上漲超過 50%。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/271704188.md"
published_at: "2026-01-06T21:47:02.000Z"
---

# 據報禮來擬以逾 10 億美元收購 Ventyx Biosciences

> 禮來正在與 Ventyx Biosciences 進行超過 10 億美元的收購談判，消息來源於《華爾街日報》。此交易可能會使禮來的產品線增加治療炎症性腸病和帕金森病的藥物。Ventyx 的一種實驗性藥物也在中期開發中，旨在治療與肥胖相關的心血管疾病。Ventyx 的股價在盤後交易中上漲超過 50%。

《華爾街日報》週二引述消息報道，禮來 (LLY.US) 就擬以超過 10 億美元收購 Ventyx Biosciences(VTYX.US) 的交易進行深入談判。Ventyx 盤後股價飆升逾 50%。

潛在收購 Ventyx 將為禮來的產品管線增加治療炎症性腸病的藥物，以及治療帕金森等疾病的藥物。此外，Ventyx 的一種實驗性藥物目前正在中期開發階段，用於治療與肥胖相關的心血管疾病。

### Related Stocks

- [VTYX.US - Ventyx Biosciences](https://longbridge.com/zh-HK/quote/VTYX.US.md)
- [LLY.US - 禮來](https://longbridge.com/zh-HK/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill | Eli Lilly (LLY) has prepared a $1.5 billion inventory of its new weight-loss pill, Orforglipron, ahead of its anticipate | [Link](https://longbridge.com/zh-HK/news/276070062.md) |
| Eli Lilly and Company $LLY Shares Acquired by Assetmark Inc. | Assetmark Inc. increased its holdings in Eli Lilly and Company (NYSE: LLY) by 6.0% in Q3, owning 55,360 shares valued at | [Link](https://longbridge.com/zh-HK/news/275971336.md) |
| Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co statement | Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co | [Link](https://longbridge.com/zh-HK/news/275551012.md) |
| Short Interest in Schneider Electric SE (OTCMKTS:SBGSY) Drops By 16.8% | Schneider Electric SE (OTCMKTS:SBGSY) experienced a 16.8% decrease in short interest in January, with 197,858 shares sho | [Link](https://longbridge.com/zh-HK/news/276071356.md) |
| CICC Reaffirms Their Buy Rating on NIO Inc. Class A (9866) | CICC analyst maintained a Buy rating on NIO Inc. Class A yesterday and set a price target of HK$50.00.Valentine's Day Sa | [Link](https://longbridge.com/zh-HK/news/275967598.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。